DESIGN OPTIMIZATION AND EVALUATION OPHTHALMIC NANOEMULSION
Main Article Content
Keywords
Olapatadine, Opthalmic Nanoemulsion
Abstract
Nanoparticulate ophthalmic drug delivery systems enhances the bioavailability of poorly water soluble drugs. It is an isotropic mixture of Oil, Surfactant, Cosurfactant (Smix), water and drug. Nanoemulsion, particularly, oil/water nanoemulsions have been investigated as a potential drug delivery system. Nanoemulsion possesses unique physicochemical properties namely, high solubilizing capacity for various drugs as well as acting as penetration enhancers to facilitate corneal drug delivery. Furthermore, the low surface tension of nanoemulsion would also guarantee a good spreading effect on the cornea and a proper mixing with the precorneal film constituents, thus would possibly improve the contact between the drug and corneal epithelium. Nanoemulsionhave good tissue permeability because of small size of micelles and the presence of surfactant among the components.
References
1. Abou el Ela A. E. S. F., Khatib M. M. E. (2013), “Formulation and evaluation of new long acting metoprololtartrate ophthalmic gels”, Saudi pharmaceuticaljournal, 22, 555- 563.
2. Achouri D., Alhanout K., Piccerelle P., Andrieu V. (2012), “Recent advances in ocular drug delivery”, Drug development and industrial pharmacy, 1–19.
3. Amo E. and M., Urtti A. (2008), “Current and future ophthalmic drug delivery systems A shift to the posterior segment”, Drug discovery today, 13, 3-4.
4. Azari A. A., Barney N. P. (2013), “Conjunctivitis: A Systematic Review of Diagnosis and Treatment”, Journal of american medical association, 310(16), 1721–1729.
5. Birch D. G., Liang F. Q. (2007), “Age-related macular degeneration: a target for nanotechnology derived medicines”, International journal of nanomedicine, 2(1), 65–77.
6. Bressler N. M. (2004), “Age-related macular degeneration is the leading cause of blindness”, Archives ophthalmology, 122, 564-572.
7. Braunger B. M., Fuchshofer R., Tamm E. R. (2015), “The aqueous humor outflow pathways in glaucoma: A unifying concept of disease mechanisms and causative treatment”, European journal of pharmaceutics and biopharmaceutics, 1-39.
8. Campochiaro PA., (2006), Potential application for RNAi to probpathogenesin and develope new treatments for ocular disorders, Gene therapy, 2006;13:559-562.
9. C. Lim, D.-w. Kim, T. Sim, N.H. Hoang, J.W. Lee, E.S. Lee, Y.S. Youn, K.T.(2016), Oh, Prepara-tion and characterization of a lutein loading nanoemulsion system for ophthalmiceye drops, J. Drug Deliv. Sci. Technol. 36,168–174.
10. Chavan, S., Petkar, K., Sawant, K., (2013). Simvastatin nanoemulsion for improved oral delivery: design, characterisation, in vitro and in vivo studies. J. Microencap. 30(8), 771–779.
11. Chime, S., Kenechukwu, F., Attama, A., (2014). Nanoemulsions - advances in formulation, characterization and applications in drug delivery. Intech Open Ltd., London, UK.
12. Cholkar K., Reddy S. Pal D., Mitra A. K., (2013), “Eye: anatomy, physiology and barriers to drug delivery” Woodhead publishing limited, 1-36.
13. Dhat, S., Pund, S., kokare, C., Sharma, P., Shrivastava, B.,(2016). Mechanistic investigation of biopharmaceutic and pharmacokinetic characteristics of surface engineering of satranidazolenanocrystals.Eur. J. Pharm. Sci. 100, 109-118.
14. DelMonte D. W., Kim T. (2011), “Anatomy and physiology of the cornea”, Journal ofcataract refract surgery, 37, 588-598.
15. Denis P., Covert D., Realini A. (2007), “Travoprost in the management of open-angle glaucoma and ocular hypertension”, Clinical ophthalmology, 1(1), 11–24.
16. Distelhorst J. S., Hughes G. M. (2003), “Open Angle Glaucoma”, American Family physician, 67 (9), 1937-1944.
17. F. Gao, Z. Zhang, H. Bu, Y. Huang, Z. Gao, J. Shen, C. Zhao, Y. Li,(2011) Nanoemulsion improves the oral absorption of condensartancilexetilin rats: Performance and mechanism, Journal of controlled release: official journal ofthe Controlled Release Society, 149, 168-174.
18. Gallarate, M., Chirio, D., Bussano, R., Peira, E., Battaglia, L., Baratta, F., Trotta, M., (2013).Development of O/W nanoemulsions for ophthalmic administration of timolol.Int. J. Pharm. 440, 126–134.
19. Ganta S., P. Sharma, J.W. Paxton, B.C. Baguley, S. Garg,(2010) Pharmacokinetics and phar-macodynamics of chlorambucil delivered in long-circulating nanoemulsion, J. DrugTarget. 18, 125–133.
20. Grapentin C., Bernert S., Schubert R., (2015) Monitoring the Stability of PerfluorocarbonNanoemulsions by Cryo-TEM Image Analysis and Dynamic Light Scattering, 2 (1), 12-22.
21. Gupta A., Manocha N. (2012), “Formulation and evaluation of in-situ ophthalmic drug delivery system”, International journal of pharmaceutical & biological archives, 3 (4), 715-718.
22. Gupta S., Samanta M., Raichur A. (2010), “Dual-drug delivery system based on in situ gel - forming nanosuspension of forskolin to enhance antiglaucoma efficacy”, American association of pharmaceutical scientists, 2(1), 322-334.
23. Gupta, A., Eral, H., Hatton, T., Doyel, P., (2016).Nanoemulsions: formation, properties and applications. Soft Matt. 12, 10-39.
24. Gupta, S., Samanta, M. &Raichur, A. (2010). Dual –drug delivery system based on in situ gel- forming nanosuspension of forskolin to enhance antiglaucoma efficacy. AAPS PharmSciTech. 2(1), 322-334.
25. Sun H., K. Liu, W. Wang, C. Guo, B. Tang, J. Gu, J. Zhang, H. Li, X. Mao, Q. Zou, H. Zeng, (2012), Development and characterization of novel nanoemulsion drug –delivery system for potential application in oral delivery of protein drugs, International journal of nanomedicine, 7, 5529-5543.
26. H. Yu, Q. Huang, (2012) Improving the Oral Bioavailability of Curcumin Using Novel Organogel-Based Nanoemulsions, Journal of Agricuitural and Food Chemistry, 60, 5373-5379.
27. Hagigit T., M. Abdulrazik, F. Orucov, F. Valamanesh, M. Lambert, G. Lambert, F.Behar-Cohen, S. Benita, (2010) Topical and intravitreous administration of cationic nanoemulsions to deliver antisense oligonucleotides directed towards VEGF KDR receptors to the eye, J. Control. Release 145, 297–305.
28. Handbook of pharmaceutical excipients, (2013),Pharmaceutical development and technology,7, 221-226.
29. Indian Pharmacopoeia (2018), The Indian Pharmacopoeia commission Ghaziabad, India, 27-58.
30. International Conference on Harmonization Guideline on stability testing of New Drug Substances and Products; Q2A (R1), 2010, Geneva.
31. Jasmina H., Dzana, O., Alisa, E., Edina, V., Ognjenka, R., (2017).Preparation of nanoemulsion by high energy and low energy emulsification methods.International Federation for Medical and Biological Engineering Proceedings.317-322.
32. Jitendra, Sharma P. K., Banik A., Dixit S. (2011), “A new trend: ocular drug delivery system”, International journal of pharmaceutical sciences, 2, 1-25.
33. Jindal V. (2013), “Glaucoma a multifactorial disease and its multidimensional management”, International journal of scientific and research publications, 3, 1-3.
34. Karthika K., Arul Kumaran K. S. G., Padmapreetha J. (2010), “Comparative review on conventional and advanced ocular drug delivery formulations” International journal of pharmacy and pharmaceutical sciences, 2(4), 1-5.
35. Khandavilli S., Panchagnula R.,(2007), Nanoemulsions as versatile formulations for pacli-taxel delivery: peroral and dermal delivery studies in rats, J. Investig. Dermatol.127, 154–162.
36. Singh K. K., Vingkar S. K., (2008), Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine, Int. J. Pharm. 347, 136–143.
37. Kumar S. K. P., Bhowmik D, Harish G., Duraivel S., Kumar P. B. (2012), “Ocular Inserts: A Novel Controlled Drug Delivery System”, The Pharma Innovation, 1(12), 1-16.
38. Kuno N., Fujii S. (2011), “Recent advances in ocular drug delivery systems”, Polymers, 3, 193-221.
39. L. Wang, X. Li, G. Zhang, J. Dong and J. Eastoe, (2007), “Oil-in-Water Nanoemulsions for Pesticide Formula- tions,” Journal of Colloid and Interface Science, 314, (1), 230-235.
40. Lalla, K., Gurnaney, A., Narayanan, S., (2002). Permeation of diclofenac through buccal mucosa.Indian J. Pharm. Sci. 64(4), 373-377.
41. Lemij H. G., Hoevenaars J. G. Windt C. v., Baudouin C. (2015), “Patient satisfaction with glaucoma therapy: reality or myth?” Clinical ophthalmology, 9, 785-793.
42. Li, T., T. Wang, H.B.He, X. Tang, (2008).The properties of bufadienolides-loaded nano-emulsion and submicro-emulsion during lyophilization.Int. J. Pharm., 349: 291-299. DOI: 10.1016/j.ijpharm.2007.08.011.
43. Lu, R., Liu, S., Wang, Q., Li, X., (2015), Nanoemulsions as novel oral carriers of stiripentol: insights into the protective effect and absorption enhancement. Int.J. Nanomed. 10, 4937-4946.
44. M. J. Barea, M. J. Jekins, M. H. Gaber, et al., (2010), “Evaluation of Liposomes Coated with a pH Responsive Polymer,” International Journal ofPharmaceutics, Vol. 402, No. 1, 89-94.
45. Madan M., Bajaj A., Lewis S., Udupa N., Baig J.A. (2009), “In situ forming polymeric drug delivery systems” Indian journal of pharmaceutical sciences, 73(3), 242-251.
46. Makwana S. B., Patel V. A., Parmar S. J. (2016), “Development and characterization of in-situ gel for ophthalmic formulation containing ciprofloxacin hydrochloride” Results in pharma sciences, 6, 1-6.
47. McClements D. J., (2012), Nanoemulsion versus microemulsion: terminology, differences, and similarities, Soft Matter, 8, 1719-1729.
48. Morsi, N., Ibrahim, M., Refai, H. and El Sorogy, H., (2017),.Nanoemulsion-based electrolyte triggered in situ gel for ocular delivery of acetazolamide. EuropeanJournal of Pharmaceutical Sciences, 104, 302-314.
49. Mou, D., Chen, H., Du, D., Mao, C., Wan, J., Xu, H. and Yang, X., (2008).Hydrogel-thickened nanoemulsion system for topical delivery of lipophilic drugs.International Journal of Pharmaceutics, 353(1-2), 270-276.
50. Netland P. A., Landry T., Sullivan E. K., Andrew R., Silver L., Weiner A., Mallick S., Dickerson J., Bergamini M. V., Robertson S. M., Davis A. A., (2001), “Travoprost compared with latanoprost and timolol in patients with open angle glaucoma or ocular hypertension”, American journal of ophthalmology, 132, 72-84.
51. Patel A., Cholkar K., Agrahari V., Mitra A. K. (2013), “Ocular drug delivery systems: An overview”, World journal pharmacology, 2(2), 47–64.
52. Patil A. P., Tagalpallewar A. A., Rasve G. M., Bendre A. V., Khapekar P. G. (2012), “Novel ophthalmic drug delivery systems: in situ gel”, International Journal of pharmaceutics and research, 3, 2938-2946.
53. Pandya, T. P., Modasiya, M. K., Patel V. M. (2011), “Ophthalmic in situ gelling system” International journal of pharmaceutics, 2, 730-738.
54. Prajapati, M., Patel, N., Bariya, A., Patel, S., Butani, S., (2017).Formulation and evaluation of self emulsifying drug delivery system for nimodipine, a BCS class II drug, J. Drug Deliv. Sci. Technol. 16(1), 286-298.
55. Prajapati, S., Joshi, H., Patel, C., (2013),. Preparation and characterization of self-microemulsifying drug delivery system of olmesartan.
56. Rajoria G., Gupta A. (2012), “In- situ gelling system: a novel approach for ocular drug delivery”, American journal of pharmtech research, 2 (4), 24-53.
57. S. Ganta, P. Sharma, J. W. Paxton, B. C. Baguley, S. Garg, (2010), Pharmacokinetics and Pharmacodynamics of chlorambucinol delivered in long-circulatingnanoemulsion, Journal of drug targeting, 18, 125-133.
58. S. Khandavilli, R. Panchagnula, (2007), Nanoemulsion as Versatile Formulations for Paclitaxel Delivery: Peroral and Dermal Delivery Studies in Rats, Journal of Investigative Dermatology, 127, 154-162.
59. Sawant D., Dandagi P. M., Gadad A. P. (2016), “Formulation and evaluation of sparfloxacinemulsomes-loaded thermosensitive in situ gel for ophthalmic delivery”, Journal of Sol-Gel science and technology, 77, 654–665.
60. Sawant, S., Bodhankar, S., (2016). Flax Lignan Concentrate Ameliorates Nω-Nitro-L-Arginine Methyl Ester (L-NAME)-Induced Hypertension: Role of Antioxidant, Angiotensin-Converting Enzyme and Nitric Oxide. Pharmacologia. 7(4), 157-159.
61. Setya, S., Talegaonkar, S., Razdan, B.K., (2014).Nanoemulsions: formulation methods and stability aspects. World J. Pharm. Pharm. Sci. 3(2), 2214-2228
62. Sharma A., Kumar P., (2010), Understanding implantation window, a crucial phenomenon, Chronicles of Young Scientists, 1, 2-6.
63. Srividya, B., Cardoza, R.M., Amin, P.D., (2001). Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J. Control. Release 73, 205–211.
64. S. Asthana, A.K. Jaiswal, P. K. Gupta, V.K. Pawar, A. Dube, M. K. Chourasia, (2013), Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template- based chitosan nanocapsule, Antimicrobe Agents Chemother, 57 ,1714-1722.
65. T. G. Mason, J. Wilking, K. Meleson, C. Chang, S. Graves, (2006), Nanoemulsion: formation, structure, and physical properties, Journal of Physics: CondensedMatter, 18, R635.
66. Tagne JB, Kakumanu S, Nicolosi RJ. Nanoemulsionformulation of the anticancer drug dacarbazine significantly increase its efficacy in a xenograft mouse melanoma model. Mol Pharm 2008; 5: 1055-63.
67. Tayel, S.A., El-Nabarawi, M.A., Tadros, M.I., Abd-Elsalam, W.H., (2013). Promising ion- sensitive in situ ocular nanoemulsion gels of terbinafine hydrochloride: design, in vitro characterization and in vivo estimation of the ocular irritation and drug pharmacokinetics in the aqueous humor of rabbits. Int. J. Pharm. 443, 293–305.
68. Tortora, G. J., Derricksons, B. (2006), “Principles of anatomy and physiology” John willey and sons, Inc, 11th edition, 5, 85-92.
69. The merck index,(2006), merk research laboratories, merck& co., inc.whitehouse station, NJ, USA, 14, 1178-1179
70. Vandamme F. (2002), “Microemulsions as ocular drug delivery systems: recent developments and future challenges”, Progress in retinal and eye research, 21, 15-34.
71. Visscher K. L., Hutnik C. M. L., Thomas M. (2009), “Evidence-based treatment of acute infective conjunctivitis”, Canadian family physician, 55, 1071-1075.
72. Wang, X., Jiang, Y., wang, Y., Huang, M., Ho, C., Huang, Q., (2008).Enhancing anti-inflammation activity of curcumin through O/W nanoemulsions.J. FoodChem. 108, 419-424.
73. Xinminga L., Yingdea C., Lloydb, A. W., Sergey V. Mikhalovskyb., Sandemanb S.R., Howelb C. A., Liewenc L. (2008), “Polymeric hydrogels for novel contact lensbased ophthalmic drug delivery systems: A review”, Contact lens and anterior eye, 32(2), 57-64.
74. Zetterberg M. (2015), “Age-related eye disease and gender”, Maturitas, 1-8.
75. Zhang X., J. Qi, Y. Xie, S. Hu, Y. Xu, Y. Lu, W. Wu, (2013), Nanoemulsions coated with alginate/chitosan as oral insulin delivery systems: preparation, characterization, and hypoglycemic effect in rats, International Journal of Nanomedicine, 8, 23-32.
2. Achouri D., Alhanout K., Piccerelle P., Andrieu V. (2012), “Recent advances in ocular drug delivery”, Drug development and industrial pharmacy, 1–19.
3. Amo E. and M., Urtti A. (2008), “Current and future ophthalmic drug delivery systems A shift to the posterior segment”, Drug discovery today, 13, 3-4.
4. Azari A. A., Barney N. P. (2013), “Conjunctivitis: A Systematic Review of Diagnosis and Treatment”, Journal of american medical association, 310(16), 1721–1729.
5. Birch D. G., Liang F. Q. (2007), “Age-related macular degeneration: a target for nanotechnology derived medicines”, International journal of nanomedicine, 2(1), 65–77.
6. Bressler N. M. (2004), “Age-related macular degeneration is the leading cause of blindness”, Archives ophthalmology, 122, 564-572.
7. Braunger B. M., Fuchshofer R., Tamm E. R. (2015), “The aqueous humor outflow pathways in glaucoma: A unifying concept of disease mechanisms and causative treatment”, European journal of pharmaceutics and biopharmaceutics, 1-39.
8. Campochiaro PA., (2006), Potential application for RNAi to probpathogenesin and develope new treatments for ocular disorders, Gene therapy, 2006;13:559-562.
9. C. Lim, D.-w. Kim, T. Sim, N.H. Hoang, J.W. Lee, E.S. Lee, Y.S. Youn, K.T.(2016), Oh, Prepara-tion and characterization of a lutein loading nanoemulsion system for ophthalmiceye drops, J. Drug Deliv. Sci. Technol. 36,168–174.
10. Chavan, S., Petkar, K., Sawant, K., (2013). Simvastatin nanoemulsion for improved oral delivery: design, characterisation, in vitro and in vivo studies. J. Microencap. 30(8), 771–779.
11. Chime, S., Kenechukwu, F., Attama, A., (2014). Nanoemulsions - advances in formulation, characterization and applications in drug delivery. Intech Open Ltd., London, UK.
12. Cholkar K., Reddy S. Pal D., Mitra A. K., (2013), “Eye: anatomy, physiology and barriers to drug delivery” Woodhead publishing limited, 1-36.
13. Dhat, S., Pund, S., kokare, C., Sharma, P., Shrivastava, B.,(2016). Mechanistic investigation of biopharmaceutic and pharmacokinetic characteristics of surface engineering of satranidazolenanocrystals.Eur. J. Pharm. Sci. 100, 109-118.
14. DelMonte D. W., Kim T. (2011), “Anatomy and physiology of the cornea”, Journal ofcataract refract surgery, 37, 588-598.
15. Denis P., Covert D., Realini A. (2007), “Travoprost in the management of open-angle glaucoma and ocular hypertension”, Clinical ophthalmology, 1(1), 11–24.
16. Distelhorst J. S., Hughes G. M. (2003), “Open Angle Glaucoma”, American Family physician, 67 (9), 1937-1944.
17. F. Gao, Z. Zhang, H. Bu, Y. Huang, Z. Gao, J. Shen, C. Zhao, Y. Li,(2011) Nanoemulsion improves the oral absorption of condensartancilexetilin rats: Performance and mechanism, Journal of controlled release: official journal ofthe Controlled Release Society, 149, 168-174.
18. Gallarate, M., Chirio, D., Bussano, R., Peira, E., Battaglia, L., Baratta, F., Trotta, M., (2013).Development of O/W nanoemulsions for ophthalmic administration of timolol.Int. J. Pharm. 440, 126–134.
19. Ganta S., P. Sharma, J.W. Paxton, B.C. Baguley, S. Garg,(2010) Pharmacokinetics and phar-macodynamics of chlorambucil delivered in long-circulating nanoemulsion, J. DrugTarget. 18, 125–133.
20. Grapentin C., Bernert S., Schubert R., (2015) Monitoring the Stability of PerfluorocarbonNanoemulsions by Cryo-TEM Image Analysis and Dynamic Light Scattering, 2 (1), 12-22.
21. Gupta A., Manocha N. (2012), “Formulation and evaluation of in-situ ophthalmic drug delivery system”, International journal of pharmaceutical & biological archives, 3 (4), 715-718.
22. Gupta S., Samanta M., Raichur A. (2010), “Dual-drug delivery system based on in situ gel - forming nanosuspension of forskolin to enhance antiglaucoma efficacy”, American association of pharmaceutical scientists, 2(1), 322-334.
23. Gupta, A., Eral, H., Hatton, T., Doyel, P., (2016).Nanoemulsions: formation, properties and applications. Soft Matt. 12, 10-39.
24. Gupta, S., Samanta, M. &Raichur, A. (2010). Dual –drug delivery system based on in situ gel- forming nanosuspension of forskolin to enhance antiglaucoma efficacy. AAPS PharmSciTech. 2(1), 322-334.
25. Sun H., K. Liu, W. Wang, C. Guo, B. Tang, J. Gu, J. Zhang, H. Li, X. Mao, Q. Zou, H. Zeng, (2012), Development and characterization of novel nanoemulsion drug –delivery system for potential application in oral delivery of protein drugs, International journal of nanomedicine, 7, 5529-5543.
26. H. Yu, Q. Huang, (2012) Improving the Oral Bioavailability of Curcumin Using Novel Organogel-Based Nanoemulsions, Journal of Agricuitural and Food Chemistry, 60, 5373-5379.
27. Hagigit T., M. Abdulrazik, F. Orucov, F. Valamanesh, M. Lambert, G. Lambert, F.Behar-Cohen, S. Benita, (2010) Topical and intravitreous administration of cationic nanoemulsions to deliver antisense oligonucleotides directed towards VEGF KDR receptors to the eye, J. Control. Release 145, 297–305.
28. Handbook of pharmaceutical excipients, (2013),Pharmaceutical development and technology,7, 221-226.
29. Indian Pharmacopoeia (2018), The Indian Pharmacopoeia commission Ghaziabad, India, 27-58.
30. International Conference on Harmonization Guideline on stability testing of New Drug Substances and Products; Q2A (R1), 2010, Geneva.
31. Jasmina H., Dzana, O., Alisa, E., Edina, V., Ognjenka, R., (2017).Preparation of nanoemulsion by high energy and low energy emulsification methods.International Federation for Medical and Biological Engineering Proceedings.317-322.
32. Jitendra, Sharma P. K., Banik A., Dixit S. (2011), “A new trend: ocular drug delivery system”, International journal of pharmaceutical sciences, 2, 1-25.
33. Jindal V. (2013), “Glaucoma a multifactorial disease and its multidimensional management”, International journal of scientific and research publications, 3, 1-3.
34. Karthika K., Arul Kumaran K. S. G., Padmapreetha J. (2010), “Comparative review on conventional and advanced ocular drug delivery formulations” International journal of pharmacy and pharmaceutical sciences, 2(4), 1-5.
35. Khandavilli S., Panchagnula R.,(2007), Nanoemulsions as versatile formulations for pacli-taxel delivery: peroral and dermal delivery studies in rats, J. Investig. Dermatol.127, 154–162.
36. Singh K. K., Vingkar S. K., (2008), Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine, Int. J. Pharm. 347, 136–143.
37. Kumar S. K. P., Bhowmik D, Harish G., Duraivel S., Kumar P. B. (2012), “Ocular Inserts: A Novel Controlled Drug Delivery System”, The Pharma Innovation, 1(12), 1-16.
38. Kuno N., Fujii S. (2011), “Recent advances in ocular drug delivery systems”, Polymers, 3, 193-221.
39. L. Wang, X. Li, G. Zhang, J. Dong and J. Eastoe, (2007), “Oil-in-Water Nanoemulsions for Pesticide Formula- tions,” Journal of Colloid and Interface Science, 314, (1), 230-235.
40. Lalla, K., Gurnaney, A., Narayanan, S., (2002). Permeation of diclofenac through buccal mucosa.Indian J. Pharm. Sci. 64(4), 373-377.
41. Lemij H. G., Hoevenaars J. G. Windt C. v., Baudouin C. (2015), “Patient satisfaction with glaucoma therapy: reality or myth?” Clinical ophthalmology, 9, 785-793.
42. Li, T., T. Wang, H.B.He, X. Tang, (2008).The properties of bufadienolides-loaded nano-emulsion and submicro-emulsion during lyophilization.Int. J. Pharm., 349: 291-299. DOI: 10.1016/j.ijpharm.2007.08.011.
43. Lu, R., Liu, S., Wang, Q., Li, X., (2015), Nanoemulsions as novel oral carriers of stiripentol: insights into the protective effect and absorption enhancement. Int.J. Nanomed. 10, 4937-4946.
44. M. J. Barea, M. J. Jekins, M. H. Gaber, et al., (2010), “Evaluation of Liposomes Coated with a pH Responsive Polymer,” International Journal ofPharmaceutics, Vol. 402, No. 1, 89-94.
45. Madan M., Bajaj A., Lewis S., Udupa N., Baig J.A. (2009), “In situ forming polymeric drug delivery systems” Indian journal of pharmaceutical sciences, 73(3), 242-251.
46. Makwana S. B., Patel V. A., Parmar S. J. (2016), “Development and characterization of in-situ gel for ophthalmic formulation containing ciprofloxacin hydrochloride” Results in pharma sciences, 6, 1-6.
47. McClements D. J., (2012), Nanoemulsion versus microemulsion: terminology, differences, and similarities, Soft Matter, 8, 1719-1729.
48. Morsi, N., Ibrahim, M., Refai, H. and El Sorogy, H., (2017),.Nanoemulsion-based electrolyte triggered in situ gel for ocular delivery of acetazolamide. EuropeanJournal of Pharmaceutical Sciences, 104, 302-314.
49. Mou, D., Chen, H., Du, D., Mao, C., Wan, J., Xu, H. and Yang, X., (2008).Hydrogel-thickened nanoemulsion system for topical delivery of lipophilic drugs.International Journal of Pharmaceutics, 353(1-2), 270-276.
50. Netland P. A., Landry T., Sullivan E. K., Andrew R., Silver L., Weiner A., Mallick S., Dickerson J., Bergamini M. V., Robertson S. M., Davis A. A., (2001), “Travoprost compared with latanoprost and timolol in patients with open angle glaucoma or ocular hypertension”, American journal of ophthalmology, 132, 72-84.
51. Patel A., Cholkar K., Agrahari V., Mitra A. K. (2013), “Ocular drug delivery systems: An overview”, World journal pharmacology, 2(2), 47–64.
52. Patil A. P., Tagalpallewar A. A., Rasve G. M., Bendre A. V., Khapekar P. G. (2012), “Novel ophthalmic drug delivery systems: in situ gel”, International Journal of pharmaceutics and research, 3, 2938-2946.
53. Pandya, T. P., Modasiya, M. K., Patel V. M. (2011), “Ophthalmic in situ gelling system” International journal of pharmaceutics, 2, 730-738.
54. Prajapati, M., Patel, N., Bariya, A., Patel, S., Butani, S., (2017).Formulation and evaluation of self emulsifying drug delivery system for nimodipine, a BCS class II drug, J. Drug Deliv. Sci. Technol. 16(1), 286-298.
55. Prajapati, S., Joshi, H., Patel, C., (2013),. Preparation and characterization of self-microemulsifying drug delivery system of olmesartan.
56. Rajoria G., Gupta A. (2012), “In- situ gelling system: a novel approach for ocular drug delivery”, American journal of pharmtech research, 2 (4), 24-53.
57. S. Ganta, P. Sharma, J. W. Paxton, B. C. Baguley, S. Garg, (2010), Pharmacokinetics and Pharmacodynamics of chlorambucinol delivered in long-circulatingnanoemulsion, Journal of drug targeting, 18, 125-133.
58. S. Khandavilli, R. Panchagnula, (2007), Nanoemulsion as Versatile Formulations for Paclitaxel Delivery: Peroral and Dermal Delivery Studies in Rats, Journal of Investigative Dermatology, 127, 154-162.
59. Sawant D., Dandagi P. M., Gadad A. P. (2016), “Formulation and evaluation of sparfloxacinemulsomes-loaded thermosensitive in situ gel for ophthalmic delivery”, Journal of Sol-Gel science and technology, 77, 654–665.
60. Sawant, S., Bodhankar, S., (2016). Flax Lignan Concentrate Ameliorates Nω-Nitro-L-Arginine Methyl Ester (L-NAME)-Induced Hypertension: Role of Antioxidant, Angiotensin-Converting Enzyme and Nitric Oxide. Pharmacologia. 7(4), 157-159.
61. Setya, S., Talegaonkar, S., Razdan, B.K., (2014).Nanoemulsions: formulation methods and stability aspects. World J. Pharm. Pharm. Sci. 3(2), 2214-2228
62. Sharma A., Kumar P., (2010), Understanding implantation window, a crucial phenomenon, Chronicles of Young Scientists, 1, 2-6.
63. Srividya, B., Cardoza, R.M., Amin, P.D., (2001). Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J. Control. Release 73, 205–211.
64. S. Asthana, A.K. Jaiswal, P. K. Gupta, V.K. Pawar, A. Dube, M. K. Chourasia, (2013), Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template- based chitosan nanocapsule, Antimicrobe Agents Chemother, 57 ,1714-1722.
65. T. G. Mason, J. Wilking, K. Meleson, C. Chang, S. Graves, (2006), Nanoemulsion: formation, structure, and physical properties, Journal of Physics: CondensedMatter, 18, R635.
66. Tagne JB, Kakumanu S, Nicolosi RJ. Nanoemulsionformulation of the anticancer drug dacarbazine significantly increase its efficacy in a xenograft mouse melanoma model. Mol Pharm 2008; 5: 1055-63.
67. Tayel, S.A., El-Nabarawi, M.A., Tadros, M.I., Abd-Elsalam, W.H., (2013). Promising ion- sensitive in situ ocular nanoemulsion gels of terbinafine hydrochloride: design, in vitro characterization and in vivo estimation of the ocular irritation and drug pharmacokinetics in the aqueous humor of rabbits. Int. J. Pharm. 443, 293–305.
68. Tortora, G. J., Derricksons, B. (2006), “Principles of anatomy and physiology” John willey and sons, Inc, 11th edition, 5, 85-92.
69. The merck index,(2006), merk research laboratories, merck& co., inc.whitehouse station, NJ, USA, 14, 1178-1179
70. Vandamme F. (2002), “Microemulsions as ocular drug delivery systems: recent developments and future challenges”, Progress in retinal and eye research, 21, 15-34.
71. Visscher K. L., Hutnik C. M. L., Thomas M. (2009), “Evidence-based treatment of acute infective conjunctivitis”, Canadian family physician, 55, 1071-1075.
72. Wang, X., Jiang, Y., wang, Y., Huang, M., Ho, C., Huang, Q., (2008).Enhancing anti-inflammation activity of curcumin through O/W nanoemulsions.J. FoodChem. 108, 419-424.
73. Xinminga L., Yingdea C., Lloydb, A. W., Sergey V. Mikhalovskyb., Sandemanb S.R., Howelb C. A., Liewenc L. (2008), “Polymeric hydrogels for novel contact lensbased ophthalmic drug delivery systems: A review”, Contact lens and anterior eye, 32(2), 57-64.
74. Zetterberg M. (2015), “Age-related eye disease and gender”, Maturitas, 1-8.
75. Zhang X., J. Qi, Y. Xie, S. Hu, Y. Xu, Y. Lu, W. Wu, (2013), Nanoemulsions coated with alginate/chitosan as oral insulin delivery systems: preparation, characterization, and hypoglycemic effect in rats, International Journal of Nanomedicine, 8, 23-32.
Article Sidebar
Published
Jan 16, 2024
Article Details
How to Cite
Madhavi Ruchake, Dr. Amol Tagalpallewar, Yashwant Nakhate, & Pranali Kalambe. (2024). DESIGN OPTIMIZATION AND EVALUATION OPHTHALMIC NANOEMULSION. Journal of Population Therapeutics and Clinical Pharmacology, 31(1), 1927–1942. https://doi.org/10.53555/jptcp.v31i1.4275
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Author Biographies
Madhavi Ruchake
Department of Pharmaceutics, Sinhgad Technical Education Society’s, Sinhgad Institute of Pharmacy (Affiliated to Savitribai Phule Pune University), Narhe, Pune, 411014, Maharashtra, India.
Dr. Amol Tagalpallewar
Department of Pharmaceutics, Sinhgad Technical Education Society’s, Sinhgad Institute of Pharmacy (Affiliated to Savitribai Phule Pune University), Narhe, Pune, 411014, Maharashtra, India.
Yashwant Nakhate
Assistant Professor, Department of Pharmacognosy, School of Pharmacy, G.H. Raisoni University, Amravati, Maharashtra, India- 444701
Pranali Kalambe
Department of Pharmacology, Dr. Arun Motghare College of Pharmacy, Kosra-konda, Maharashtra, India-441908